Dore GJ - Search Results

1

Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.

Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanant N, Matthews GV, Dore GJ, Bowden S, Lange J, Ruxrungtham K. Avihingsanon A, et al. Among authors: dore gj. Antivir Ther. 2010;15(6):917-22. doi: 10.3851/IMP1645. Antivir Ther. 2010. PMID: 20834105 Clinical Trial.

2

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database. Lincoln D, et al. Among authors: dore gj. HIV Med. 2003 Jul;4(3):241-9. doi: 10.1046/j.1468-1293.2003.00152.x. HIV Med. 2003. PMID: 12859323 Free article.

3

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA. Law WP, et al. Among authors: dore gj. AIDS. 2003 Oct 17;17(15):2191-9. doi: 10.1097/00002030-200310170-00007. AIDS. 2003. PMID: 14523276

4

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK; 903 Study Team; 907 Study Team. Dore GJ, et al. J Infect Dis. 2004 Apr 1;189(7):1185-92. doi: 10.1086/380398. Epub 2004 Mar 12. J Infect Dis. 2004. PMID: 15031786 Clinical Trial.

5

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Law WP, et al. Among authors: dore gj. AIDS. 2004 May 21;18(8):1169-77. doi: 10.1097/00002030-200405210-00010. AIDS. 2004. PMID: 15166532 Clinical Trial.

6

HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.

Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA. Duncombe C, et al. Among authors: dore gj. AIDS. 2005 Jan 28;19(2):169-78. doi: 10.1097/00002030-200501280-00009. AIDS. 2005. PMID: 15668542

7

Treatment for hepatitis C virus infection among current injection drug users in Australia.

Matthews G, Kronborg IJ, Dore GJ. Matthews G, et al. Among authors: dore gj. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9. doi: 10.1086/427448. Clin Infect Dis. 2005. PMID: 15768342 Review.

8

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Matthews GV, et al. Among authors: dore gj. AIDS. 2006 Apr 4;20(6):863-70. doi: 10.1097/01.aids.0000218550.85081.59. AIDS. 2006. PMID: 16549970

9

Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.

Matthews GV, Dore GJ. Matthews GV, et al. Among authors: dore gj. AIDS. 2007 Mar 30;21(6):777-8. doi: 10.1097/QAD.0b013e3280b07774. AIDS. 2007. PMID: 17413705 No abstract available.

10

Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.

Matthews GV, Cooper DA, Dore GJ. Matthews GV, et al. Among authors: dore gj. Antivir Ther. 2007;12(1):119-22. Antivir Ther. 2007. PMID: 17503756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

528 results

Search Page

Filters